Evidence mapPaperPMID 39827135Full record

ArticleCardiovascular diabetology2025

ICAM1 blockade improves ischemic muscle reperfusion in diabetic mice.

Ninon Foussard, Célia Bourguignon, Virginie Grouthier, Caroline Caradu, Candice Chapouly, Alain-Pierre Gadeau, Thierry Couffinhal, Marie-Ange Renault

Abstract read
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ninon FoussardUniv. Bordeaux, Inserm, Biology of Cardiovascular Diseases, U1034, CHU de Bordeaux, 1, Avenue de Magellan, Entrée par l'Hôpital Haut-Lévêque, 33604, Pessac, France.
Célia BourguignonUniv. Bordeaux, Inserm, Biology of Cardiovascular Diseases, U1034, CHU de Bordeaux, 1, Avenue de Magellan, Entrée par l'Hôpital Haut-Lévêque, 33604, Pessac, France.
Virginie GrouthierUniv. Bordeaux, Inserm, Biology of Cardiovascular Diseases, U1034, CHU de Bordeaux, 1, Avenue de Magellan, Entrée par l'Hôpital Haut-Lévêque, 33604, Pessac, France.
Caroline CaraduBordeaux University Hospital, Department of Vascular Surgery, 33000, Bordeaux, France.
Candice ChapoulyUniv. Bordeaux, Inserm, Biology of Cardiovascular Diseases, U1034, CHU de Bordeaux, 1, Avenue de Magellan, Entrée par l'Hôpital Haut-Lévêque, 33604, Pessac, France.
Alain-Pierre GadeauUniv. Bordeaux, Inserm, Biology of Cardiovascular Diseases, U1034, CHU de Bordeaux, 1, Avenue de Magellan, Entrée par l'Hôpital Haut-Lévêque, 33604, Pessac, France.
Thierry CouffinhalUniv. Bordeaux, Inserm, Biology of Cardiovascular Diseases, U1034, CHU de Bordeaux, 1, Avenue de Magellan, Entrée par l'Hôpital Haut-Lévêque, 33604, Pessac, France.
Marie-Ange RenaultUniv. Bordeaux, Inserm, Biology of Cardiovascular Diseases, U1034, CHU de Bordeaux, 1, Avenue de Magellan, Entrée par l'Hôpital Haut-Lévêque, 33604, Pessac, France. marie-ange.renault@inserm.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic Limb-Threatening Ischemia (CLTI) represents the most advanced stage of Peripheral Artery Disease (PAD) and is associated with dire prognosis, characterized by a substantial risk of limb amputation and diminished life expectancy. Despite significant advancements in therapeutic interventions, the underlying mechanisms precipitating the progression of PAD to CLTI remain elusive.

methodsConsidering diabetes is one of the main risk factors contributing to PAD exacerbation into CLTI, we compared hind limb ischemia recovery in HFD STZ vs. non-HFD STZ mice to identify new mechanisms responsible for the exacerbation of PAD.

resultsWe used three different mouse models of diabetes and found that blood flow recovery in HFD STZ mice is altered only from day 14 post-surgery. Consistent with this kinetics, we found that angiogenesis and myogenesis which typically occur between day five and day 14 post-surgery are not impaired in mice in which diabetes was induced by a high fat diet and streptozotocin injections (HFD STZ mice). On the contrary, we found that capillary functionality e.i. acquisition of functional intercellular junctions and immune quiescence is impaired in HFD + STZ mice. Notably, 28 days after hind limb ischemia surgery, HFD + STZ mice display significantly increased capillary permeability to IgG and significantly increased levels of ICAM1. This was associated with an increased macrophage infiltration and an impaired myocyte differentiation. Importantly, we used ICAM1-blocking antibodies to demonstrate that increased ICAM1 expression in HFD + STZ mice decreases white blood cell circulation velocity within the microcirculation, which impairs its perfusion. Notably anti-ICAM1 therapy did diminish macrophage infiltration and oxidative stress but not myopathy suggesting that myopathy characterized by small myocytes expressing higher level of MYH2 could be responsible for microangiopathy.

conclusionICAM1 expression by the microvasculature impairs ischemic muscle reperfusion in HFD + STZ mice. Importantly, the increase in blood flow between day 14 and day 90 post-HLI surgery is not associated with an increased capillary density but with an improved functionality of capillaries.

Indexed as

Chronic Limb-Threatening IschemiaDiabetes Mellitus, ExperimentalIntercellular Adhesion Molecule-1IschemiaMuscle, SkeletalPeripheral Arterial DiseaseReperfusion InjuryAnimalsDiet, High-FatHindlimbMaleMiceMice, Inbred C57BLMuscle DevelopmentNeovascularization, PhysiologicRegional Blood FlowIcam1 protein, mouseIntercellular Adhesion Molecule-1Endothelial activationLimb ischemiaMicrocirculationPerfusion

Identifiers

PMID39827135
PMCPMC11742775

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.